Sign in
CompletedPhase 2

A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia

Key facts

Who runs it
Jiangsu HengRui Medicine Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
120 people enrolled
Started
10 Apr 2025
Ended
9 Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • HRS-8427
  • Meropenem
Record updated
22 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Be able and willing to provide a written informed consent before the study, fully understand the study and be able to complete the study according to the protocol
  • Male and female, ≥18 years
  • Judged by the investigator, clinical diagnosis with HABP/VABP, expectation that the patients will require hospitalization and initial treatment with intravenous antibiotics
  • All subjects must have a chest radiograph during screening or within 48h before randomization, showing the presence of new or progressive infiltrate(s) suggestive of bacterial pneumonia
  • Women of childbearing potential must have a negative serum pregnancy test before the first dose and must be non-lactating. Fertile female subjects or male subjects whose partner is a fertile female agree to use highly effective form of contraception, with no plan of birth and sperm/ovum donation from the time of signing the informed consent form (ICF) till 14 days after the end of treatment

Who cannot take part

  • Subjects who have received potentially effective antibiotic therapy for a continuous duration of more than 24 hours during the previous 72 hours prior to randomization
  • Impairment of renal function with estimated glomerular filtration rate < 15 mL/min, or receiving peritoneal dialysis/hemodialysis
  • Patients received cancer treatment within 4 weeks before randomization or planned treatment during the study period
  • Drug abuse within 1 year prior to randomization
  • Other pulmonary diseases that may confound the assessment of efficacy or safety
  • Known history of immune deficiency disease or receive immunocompromising treatment
  • Severe cardiovascular and cerebrovascular diseases with clinical significance and unstable or uncontrolled condition
  • Known or suspected central nervous system infections
  • Subjects with significant laboratory abnormalities
  • Subjects who have known or suspected community-acquired bacterial pneumonia (CABP), atypical pneumonia, or chemical pneumonia
  • Subjects who have known or suspected pneumonia caused by mycoplasma, chlamydia, legionella, viruses, fungi or parasites
  • HABP or VABP caused by obstruction
  • Judged by the Investigator, other reasons unsuitable for this study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of HRS -8427 in patients with HABP/VABP.

The 2 groups in the trial

  • HRS-8427Treatment being tested
  • MeropenemExisting treatment, for comparison

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of HRS-8427 in the Treatment of Adults With Hospital-acquired Bacterial Pneumonia (HABP) or Ventilator-associated Bacterial Pneumonia (VABP)
Publications
Record updated
22 October 2026